gutsandgrowth

Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives

Oral GLP-1 Receptor Agonist for Obesity: Orforglipron

July 21, 2023 7:00 am

S Wharton et al. NEJM 2023; DOI: 10.1056/NEJMoa2302392. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

In this phase 2 randomized, double-blind trial with 272 adults with obesity (mean weight at baseline 108 kg), participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks. “The pharmacokinetic profile of orforglipron, with a half-life of 29 to 49 hours, supports once-daily oral administration.”

Key findings:

• At week 36, the mean change ranged from −9.4% to −14.7% with orforglipron and was −2.3% with placebo.
• A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo.
• Adverse events reported with orforglipron were similar to those with injectable GLP-1 receptor agonists.

Weight reduction of at least 10% at week 36:

My take: This is an exciting time for drug development for obesity. Given the low success rates of traditional ‘lifestyle’ management approaches, these medications have the potential to reduce a great deal of morbidity. Oral agents, rather than injections, would hasten the use of these agents more broadly. Long term outcomes are still unclear.

Related blog posts:

• Weight Gain If Semaglutide Stopped
• Semaglutide in Adolescent Obesity
• Fatty Liver Disease AASLD Practice Guidance 2023
• Meds for Obesity: AAP Guidelines
• Reversing Pediatric Nonalcoholic Fatty Liver Disease
• AGA Guidelines for Adults with Obesity

Posted by gutsandgrowth

Categories: Pediatric Gastroenterology Intestinal Disorder

Tags: obesity, orforglipron, Semaglutide

« Older Newer »

Mobile Site | Full Site

Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.